Browsing by Author "Miskioglu M."

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    Primary cutaneous anaplastic CD30+ large-cell lymphoma that completely regressed after incisional skin biopsy
    (2011) Gencoglan G.; Ozturk F.; Inanir I.; Miskioglu M.; Temiz P.; Gunduz K.
    We describe a 48-year-old woman with three erythematous nodules localized on the left forearm, with 2 months evolution. Histological and immunohistochemical examination revealed a CD30+ large-cell lymphoma. Systemic involvement was not detected. The tumor regressed spontaneously within a week, after the incisional skin biopsy. In control skin biopsy, there was not any histological feature of lymphoma. No reactivation or any symptom of systemic disease was observed during the 10-month follow-up period. © 2011 Informa Healthcare USA, Inc.
  • No Thumbnail Available
    Item
    Acral amelanotic verrucous melanoma: Dermoscopic findings
    (2011) Gencoglan G.; Inanir I.; Miskioglu M.; Temiz P.
    [No abstract available]
  • No Thumbnail Available
    Item
    Evaluation of sequential effect of isotretinoin on the haematological parameters in patients with acne vulgaris
    (Taylor and Francis Ltd, 2018) Gencoglan G.; Inanir I.; Miskioglu M.; Gunduz K.
    Purpose: Isotretinoin is the most effective drug for acne with some side effects. Few studies exist regarding the effects of isotretinoin on haematological parameters with different results. Mostly, baseline values with a single value during or at the end of the treatment were compared. In this study, we aimed to determine the differences in haematological parameters during isotretinoin treatment until reaching the cumulative dose of 120 mg/kg. Materials and methods: The study included 118 patients with moderate-to-severe acne vulgaris. Patients with preexisting liver disease, anaemia, iron deficiency, abnormal liver function tests, thrombocytopenia/thrombocytosis or hyperlipidaemia were excluded. Laboratory monitoring for haematological parameters was performed at baseline and monthly during treatment. Parameters at the baseline, at the first and second months and at the end of the therapy were taken into account. Results: According to general linear model analysis, platelets and plateletcrit increased at the first month of the treatment and then decreased to baseline. White blood cells and neutrophils decreased at the first month, then increased to baseline value at the second month, and were found to be decreased again at the end of the treatment. Mean corpuscle volume was found to be increased at the end of the treatment. Other parameters in CBC did not show statistically significant differences. Conclusions: Although some changes occur in haematological parameters during isotretinoin therapy, all of these changes remain within the normal range. Evaluating the spot values at any time during treatment may cause misinterpretations. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
  • No Thumbnail Available
    Item
    Relationship of tumor-associated macrophage population detected by CD68 pg-m1, CD68 kp1, and cd163 with latent ebv infection and prognosis in classical hodgkin lymphoma
    (Federation of Turkish Pathology Societies, 2021) Mavili H.S.; Isisag A.; Tan A.; Miskioglu M.; Saka Baraz L.; Nese N.
    Objective: To evaluate the quantity of tumor-associated macrophages (TAMs) in cases of Hodgkin Lymphoma of classical type (cHL), and to reveal possible associations between TAM intensity and latent Epstein-Barr virus (EBV) infection, overall survival, progression-free survival, prognostic indices, and clinicopathological parameters. Materials and Methods: A total 46 cases of cHL with complete clinical records were selected and re-evaluated histopathologically. Staining for CD68 (PG-M1; KP1 clones) and CD163 was evaluated and the cut-off values were defined. Also, all cases were evaluated using the chromogen in situ hybridization (CISH) method with EBER (Epstein-Barr virus-encoded RNA) probes for the presence of possible EBV infection. Results: It was found that high expression levels of PG-M1 and high International Prognostic Scores (IPS) were associated with shortened overall survival (p=0.047, p=0.013). Cases with 2 or less areas of nodal region involvement were observed to have longer progression-free survival period (p=0.043). Higher expression levels of CD68 PG-M1, CD68 KP1, and CD163 were found to show significant associations with the presence of some clinical parameters such as the presence of B symptoms, spleen involvement, and the presence of EBV infection. Conclusions: Our findings suggest that increase of PG-M1+ TAM is associated with shortened overall survival, while higher expressions of all immunohistochemical markers are statistically significantly associated with the presence of EBV infection and clinical parameters mentioned above. These findings indicate that highlighting the TAM rate via macrophage markers in cases of cHL could be helpful in determining the prognostic risk groups and the relevant results should be mentioned in pathology reports. © 2021, Federation of Turkish Pathology Societies. All rights reserved.
  • No Thumbnail Available
    Item
    Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey
    (Taylor and Francis Ltd., 2023) Bakırtaş M.; Dal M.S.; Yiğenoğlu T.N.; Giden A.O.; Serin I.; Başcı S.; Kalpakci Y.; Korkmaz S.; Ekinci O.; Albayrak M.; Basturk A.; Ozatli D.; Dogu M.H.; Hacıbekiroglu T.; Çakar M.K.; Ulas T.; Miskioglu M.; Gulturk E.; Eser B.; Altuntas F.
    A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least ≥ two lines of therapy. Patients’ treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 ± 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients. © 2023 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia (Italian Society of Chemotherapy).
  • No Thumbnail Available
    Item
    Severe hypoglycemia due to insulin auto-antibodies of newly diagnosed multiple myeloma: A case report
    (Springer, 2024) Guney S.C.; Miskioglu M.; Engurulu S.F.; Cavdar G.G.; Akcura C.; Alkan S.; Ozdemir N.; Hekimsoy Z.
    Objective: Insulin autoimmune syndrome (IAS) is a rare condition that can be overlooked in the differential diagnosis of hypoglycemia. Hematologic malignancies such as multiple myeloma (MM) have been associated with IAS. Very few cases of IAS due to multiple myeloma have been reported in the literature. We wanted to present our case who applied to our clinic with severe hypoglycemia and was diagnosed with multiple myeloma-associated IAS. Case presentation: An 83-year-old male patient was admitted to our clinic with recurrent severe hypoglycemia episodes. When the patient’s plasma glucose was 37 mg/dL, insulin level was high (2266 µIU/ml), C-peptide level was relatively normal (3.44 ng/ml); cortisol and ACTH levels were also normal. No pathologic finding was detected in the abdominal MRI and Ga-68 PET/CT. Anti-insulin antibody (IAA) was tested for IAS, and the antibody level was found to be 95.9%. The patient was evaluated in terms of possible conditions that may lead to IAS. Hematology consultation was made due to the fact that the patient had anemia, chronic renal failure, and albumin/globuline discordance, and he was diagnosed with IgG kappa multiple myeloma. Bortezomib and dexamethasone treatment was initiated. A decrease in hypoglycemic symptoms was observed with chemotherapy. Conclusion: IAS should be considered in the differential diagnosis of recurrent hypoglycemia cases of unknown cause. It should be kept in mind that IAS may develop due to multiple myeloma, especially in patients with advanced age and anemia. © The Author(s), under exclusive licence to Research Society for Study of Diabetes in India 2023.